Natl Toxicol Program Tech Rep Ser. 2008 Jan(545):1-240.
Genistein is a naturally occurring isoflavone that interacts with estrogen receptors and multiple other molecular targets. Human exposure to genistein is predominantly through consumption of soy products, including soy-based infant formula and dietary supplements. Consumption of soy and genistein has been associated with a variety of beneficial effects in animals and humans, but concerns have also been raised regarding potential adverse effects of genistein, particularly with regard to reproductive toxicity and the induction or potentiation of carcinogenesis, due primarily to its weak estrogenic activity. Because of these concerns, genistein was selected as one of the compounds to be examined using a protocol designed to evaluate the effects of multigenerational and long-term exposures to doses of estrogenic agents that produce subtle reproductive tract lesions in developmentally exposed Sprague-Dawley rat pups. Results from the 2-year study are reported here, and results from the multigenerational reproductive toxicology feed study are reported separately (NTP, 2008a). Data from a preliminary dose range-finding feed study (NTP, 2007) that utilized exposure concentrations up to 1,250 ppm genistein were used to select dietary exposure concentrations of 0, 5, 100, and 500 ppm for the current study. The multigenerational reproductive toxicology study examined F(0) through F(4) generations with F(5) litters terminated at weaning and focused on reproductive endpoints (NTP, 2008a). Animals were exposed from the time that the F(0) generation was 6 weeks old through weaning of the F(3) generation, and animals of the F(0) through F(4) generations were necropsied at 20 weeks of age. The current study was a 2-year dietary study utilizing three exposure arms: continuous exposure from conception through 2 years (designated F(1) continuous, or F(1)C), exposure from conception through 20 weeks followed by control diet to 2 years [designated F(1) truncated at postnatal day (PND) 140, or F(1)T140], and exposure from conception through weaning followed by control diet to 2 years (designated F(3) truncated at PND 21, or F(3)T21). The "F(3)" designation for the F(3)T21 arm indicates that these animals were siblings of the F(3) animals from the multigenerational reproductive toxicology study (NTP, 2008a). The F(1)C and F(1)T140 animals were also siblings but were derived from a separate breeding that was identical to the procedure used to produce the F(1) generation of the multigenerational reproductive toxicology study. The animals in this study were exposed to genistein during various phases of their lives from conception until termination at 2 years, and the ingested doses varied over the course of the study. During pregnancy, the ingested doses of the dams were approximately 0, 0.5, 9, or 45 mg/kg body weight per day. During lactation, the dams' ingested doses were 0, 0.7, 15, or 75 mg/kg per day. Supplementary studies, which are described in the multigenerational reproductive toxicology study, indicated minimal transfer of genistein to pups via the dams' milk. The mean directly ingested genistein doses during the period prior to PND 140 were approximately 0.4, 8, or 44 mg/kg per day for females and 0.4, 7, or 37 mg/kg per day for males. For the period between PND 140 and the end of the study, mean ingested doses were approximately 0.3, 5, or 29 mg/kg per day for females and 0.2, 4, or 20 mg/kg per day for males. For the current study, 50 animals per sex were initially assigned to each exposure group in each arm of the study. In control groups, histopathology data from one to four additional animals that had been assigned as sentinels but that became moribund or died early were also included in the analysis and presentation. Survival was similar in all control and exposed groups and ranged from 62% to 86% for males and 43% to 64% for females. Mean body weights of 500 ppm F(1)C females were less than those of the controls throughout the study. Mean body weights of 500 ppm F(1)T140 rats were less than those of the controls throughout the study. In females of all study arms (F(1)C, F(1)T140, and F(3)T21) an early onset of aberrant estrous cycles, suggesting early reproductive senescence, was observed in the 500 ppm groups. In the F(3)T21 arm, there were also significant effects on the onset of aberrant estrous cycles in the 5 and 100 ppm groups. Pituitary gland weights were significantly increased in females in the 500 ppm groups of the F(1)C and F(1)T140 study arms and in the 100 ppm group of the F(3)T21 arm. In F(1)C females, there was a significant positive trend in the incidences of mammary gland adenoma or adenocarcinoma (combined) regardless of whether an unmodified or natural log-transformed dose scale was used in the analysis, and the incidence in the 500 ppm group was significantly greater than that in the control group. A significant negative trend occurred in the incidences of benign mammary gland fibroadenoma in F(1)C females, and the incidence in the 500 ppm group was significantly less than that in the control group. In 5 and 100 ppm F(1)T140 females, the combined incidences of adenoma and adenocarcinoma were less than those in the control or 500 ppm groups, although these were not statistically significant differences. When the natural log-transformed dose scale was used, a marginally significant positive trend occurred in the incidences of adenoma or adenocarcinoma (combined) in F(3)T21 females. There were positive trends in the incidences of adenoma or carcinoma (combined) in the pars distalis of the pituitary gland of females in the F(1)C and F(1)T140 arms, and the incidence in the 500 ppm group was significantly greater than that in the controls in the F(1)C study arm. In F(1)C males, a significant positive trend (unmodified dose scale only) occurred in the incidences of combined adenoma or carcinoma of the pancreatic islets. While the incidence in the 500 ppm group was elevated relative to that in the control group (6/49 versus 1/49), this was not statistically significant. The fact that transitional lesions (i.e., hyperplasia) were not observed combined with variable control rates in males of this substrain of rats led to the conclusion that this lesion was not likely to be related to genistein treatment.
Under the conditions of this 2-year feed study with continuous exposure to the test compound from conception through termination (F(1)C), there was no evidence of carcinogenic activity of genistein in male Sprague-Dawley rats exposed to 5, 100, or 500 ppm. There was some evidence of carcinogenic activity of genistein in female Sprague-Dawley rats based on increased incidences of mammary gland adenoma or adenocarcinoma (combined) and pituitary gland neoplasms. The incidence of benign mammary gland fibroadenoma in female rats was significantly decreased in the 500 ppm group. Under the conditions of this 2-year feed study with exposure to the test compound from conception through 20 weeks followed by control feed until termination (F(1)T140), there was no evidence of carcinogenic activity of genistein in male Sprague-Dawley rats exposed to 5, 100, or 500 ppm. There was equivocal evidence of carcinogenic activity of genistein in female Sprague-Dawley rats based on marginally increased incidences of pituitary gland neoplasms. Under the conditions of this 2-year feed study where offspring of three prior generations of animals exposed to the test compound were exposed from conception through weaning (PND 21) followed by control feed until termination (F(3)T21), there was no evidence of carcinogenic activity of genistein in male Sprague-Dawley rats exposed to 5, 100, or 500 ppm. There was equivocal evidence of carcinogenic activity of genistein in female Sprague-Dawley rats based on increased incidences of mammary gland adenoma or adenocarcinoma (combined). Exposure to genistein was also shown to accelerate the onset of aberrant estrous cycles in female Sprague-Dawley rats whether exposures were continuous or truncated at PND 140 or at weaning. The effects of genistein on estrous cycling and the incidences of common hormonally related spontaneous neoplasms of female Sprague-Dawley rats are consistent with an estrogenic mechanism of toxicity.
染料木黄酮是一种天然存在的异黄酮,可与雌激素受体及多种其他分子靶点相互作用。人类接触染料木黄酮主要通过食用大豆制品,包括大豆基婴儿配方奶粉和膳食补充剂。食用大豆和染料木黄酮已在动物和人类中产生了多种有益影响,但也有人担心染料木黄酮的潜在不良影响,特别是其生殖毒性以及致癌作用的诱导或增强,主要是由于其微弱的雌激素活性。出于这些担忧,染料木黄酮被选为使用一种方案进行检测的化合物之一,该方案旨在评估多代和长期暴露于能在发育过程中暴露的斯普拉格 - 道利大鼠幼崽中产生细微生殖道病变的雌激素剂量的影响。本文报告了为期2年的研究结果,多代生殖毒理学饲料研究的结果另行报告(NTP,2008a)。来自一项初步剂量范围查找饲料研究(NTP,2007)的数据,该研究使用高达1250 ppm染料木黄酮的暴露浓度,用于为本研究选择0、5、100和500 ppm的膳食暴露浓度。多代生殖毒理学研究检查了F(0)代至F(4)代,F(5)窝在断奶时终止,重点关注生殖终点(NTP,2008a)。动物从F(0)代6周龄开始暴露,直至F(3)代断奶,F(0)代至F(4)代的动物在20周龄时进行尸检。本研究是一项为期2年的膳食研究,采用三个暴露组:从受孕到2年连续暴露(指定为F(1)连续,或F(1)C),从受孕到20周暴露,然后在2年期间给予对照饮食[指定为F(1)在出生后第(PND)140天截断,或F(1)T140],以及从受孕到断奶暴露,然后在2年期间给予对照饮食(指定为F(3)在PND 21截断,或F(3)T21)。F(3)T21组的“F(3)”表示这些动物是多代生殖毒理学研究中F(3)动物的同窝仔(NTP,2008a)。F(1)C和F(1)T140动物也是同窝仔,但来自与多代生殖毒理学研究中产生F(1)代的程序相同的单独繁殖。本研究中的动物在从受孕到2年终止的生命各个阶段都暴露于染料木黄酮,摄入剂量在研究过程中有所变化。在怀孕期间,母鼠的摄入剂量约为每天0、0.5、9或45毫克/千克体重。在哺乳期,母鼠的摄入剂量为每天0、0.7、15或75毫克/千克。多代生殖毒理学研究中描述的补充研究表明,染料木黄酮通过母鼠乳汁向幼崽的转移极少。在PND 140之前,雌性的平均直接摄入染料木黄酮剂量约为每天0.4、8或44毫克/千克,雄性约为每天0.4、7或37毫克/千克。在PND 140至研究结束期间,雌性的平均摄入剂量约为每天0.3、5或29毫克/千克,雄性约为每天0.2、4或20毫克/千克。对于本研究,在研究的每个组的每个暴露组中最初分配50只每种性别的动物。在对照组中,分析和呈现中还包括一至四只最初作为哨兵分配但过早濒死或死亡的额外动物的组织病理学数据。所有对照组和暴露组的存活率相似,雄性为62%至86%,雌性为43%至64%。在整个研究过程中,500 ppm F(1)C雌性的平均体重低于对照组。500 ppm F(1)T140大鼠的平均体重在整个研究过程中低于对照组。在所有研究组(F(1)C、F(1)T140和F(3)T21)的雌性中,在500 ppm组中观察到异常发情周期提前开始,表明早期生殖衰老。在F(3)T21组中,5和100 ppm组中异常发情周期的开始也有显著影响。F(1)C和F(1)T140研究组的500 ppm组雌性以及F(3)T21组的100 ppm组雌性的垂体重量显著增加。在F(1)C雌性中,无论分析中使用未修正还是自然对数转换剂量量表,乳腺腺瘤或腺癌(合并)的发生率都有显著正趋势,500 ppm组的发生率显著高于对照组。F(1)C雌性中良性乳腺纤维腺瘤的发生率出现显著负趋势,500 ppm组的发生率显著低于对照组。在5和100 ppm F(1)T140雌性中,腺瘤和腺癌的合并发生率低于对照组或500 ppm组,尽管这些差异无统计学意义。当使用自然对数转换剂量量表时,F(3)T21雌性中腺瘤或腺癌(合并)的发生率有略微显著的正趋势。F(1)C和F(1)T140组雌性垂体远侧部腺瘤或癌(合并)的发生率有正趋势,F(1)C研究组中500 ppm组的发生率显著高于对照组。在F(1)C雄性中,胰岛腺瘤或癌(合并)的发生率有显著正趋势(仅未修正剂量量表)。虽然500 ppm组的发生率相对于对照组有所升高(6/49对1/49),但这无统计学意义。未观察到过渡性病变(即增生)以及该大鼠亚系雄性中不同的对照率这一事实导致得出该病变不太可能与染料木黄酮处理有关的结论。
在这项从受孕到终止连续暴露于受试化合物的2年饲料研究(F(1)C)条件下,未发现暴露于5、100或500 ppm染料木黄酮的雄性斯普拉格 - 道利大鼠有致癌活性证据。基于乳腺腺瘤或腺癌(合并)和垂体肿瘤发生率增加,有一些证据表明染料木黄酮对雌性斯普拉格 - 道利大鼠有致癌活性。500 ppm组雌性大鼠良性乳腺纤维腺瘤的发生率显著降低。在这项从受孕到20周暴露于受试化合物,然后在终止前给予对照饲料(F(1)T140)的2年饲料研究条件下,未发现暴露于5、100或500 ppm染料木黄酮的雄性斯普拉格 - 道利大鼠有致癌活性证据。基于垂体肿瘤发生率略有增加,有模棱两可的证据表明染料木黄酮对雌性斯普拉格 - 道利大鼠有致癌活性。在这项2年饲料研究条件下,前三代暴露于受试化合物的动物的后代从受孕到断奶(PND 21)暴露,然后在终止前给予对照饲料(F(3)T21),未发现暴露于5、100或500 ppm染料木黄酮的雄性斯普拉格 - 道利大鼠有致癌活性证据。基于乳腺腺瘤或腺癌(合并)发生率增加,有模棱两可的证据表明染料木黄酮对雌性斯普拉格 - 道利大鼠有致癌活性。还表明,无论暴露是连续的还是在PND 140或断奶时截断,暴露于染料木黄酮都会加速雌性斯普拉格 - 道利大鼠异常发情周期的开始。染料木黄酮对雌性斯普拉格 - 道利大鼠发情周期和常见激素相关自发肿瘤发生率的影响与雌激素毒性机制一致。